ROSY-SNCT07691970
Rollover Study for Participants Who Have Completed a Previous Clinical Study With Anifrolumab (Saphnelo) and Clinically Benefited From Continued Treatment
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 4 versions: 4 with changes below. See every version on ClinicalTrials.gov ↗
- Minor Trial sites expanded: 153 → 166 locations
- Minor Trial sites expanded: 128 → 153 locations
Notable Recruitment opened Show 4 more changesShow less
- Eligibility criteria expanded, about 15 words
- Trial sites expanded: 41 → 128 locations
- Primary and study completion dates: Dec 31, 2032 to Dec 30, 2032
- Start date changed from estimate of Sep 1, 2026 to Aug 31, 2026
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Arms and interventions
This is a single arm open-label study with the primary objective of providing continued access to anifrolumab to eligible participants who are continuing to derive clinical benefit from treatment and assessing long-term safety and tolerability of anifrolumab until participant meets one of the study discontinuation criteria.
Combination products: Anifrolumab
Drugs: Anifrolumab
Sites
166 sites in 35 countries
United States 21, Spain 14, Germany 13, France 10, Italy 10, China 8, Poland 8, Japan 6, United Kingdom 6, Brazil 5, Mexico 5, South Korea 5, Taiwan 5, Thailand 5, Austria 4, Bulgaria 4, India 4, Australia 3, Philippines 3, Portugal 3, Romania 3, Argentina 2, Belgium 2, Canada 2, Israel 2, Serbia 2, Slovakia 2, Turkey (Türkiye) 2, Chile 1, Colombia 1, Czechia 1, Greece 1, Netherlands 1, South Africa 1, Vietnam 1